Coverage of the 2021 EBMT Annual Meeting, held virtually March 14-17, 2021.
March 16, 2021
Video
Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.
March 16, 2021
Article
The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.
March 16, 2021
Article
The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.
March 15, 2021
Article
Omidubicel was associated with a significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with high-risk hematologic malignancies.